Cellid, Co., Ltd. (299660.KQ)

KRW 3965.0

(12.01%)

Revenue Summary of Cellid, Co., Ltd.

Cellid, Co., Ltd.'s latest annual revenue in 2023 was - KRW , down -100.0% from previous year.
Cellid, Co., Ltd.'s latest quarterly revenue in 2024 Q2 was 599.21 Million KRW , up 90.24% from previous quarter.
Cellid, Co., Ltd. reported a annual revenue of 480 Million KRW in annual revenue 2022, down -47.2% from previous year.
Cellid, Co., Ltd. reported a annual revenue of 909.09 Million KRW in annual revenue 2021, down 0.0% from previous year.
Cellid, Co., Ltd. reported a quarterly revenue of 599.21 Million KRW for 2024 Q2, up 90.24% from previous quarter.
Cellid, Co., Ltd. reported a quarterly revenue of - KRW for 2023 Q1, down -100.0% from previous quarter.

Annual Revenue Chart of Cellid, Co., Ltd. (2023 - 2015)

Historical Annual Revenue of Cellid, Co., Ltd. (2023 - 2015)

Year	Revenue	Revenue Growth
2023	- KRW	-100.0%
2022	480 Million KRW	-47.2%
2021	909.09 Million KRW	0.0%
2020	- KRW	0.0%
2019	- KRW	0.0%
2018	- KRW	0.0%
2017	- KRW	0.0%
2016	- KRW	-100.0%
2015	639.81 Million KRW	0.0%

Year	Revenue	Revenue Growth
2024 Q1	314.97 Million KRW	0.0%
2024 Q2	599.21 Million KRW	90.24%
2023 Q1	- KRW	-100.0%
2023 FY	- KRW	-100.0%
2023 Q4	- KRW	0.0%
2023 Q3	- KRW	0.0%
2023 Q2	- KRW	0.0%
2022 Q4	480 Million KRW	0.0%
2022 FY	480 Million KRW	-47.2%
2022 Q1	- KRW	100.0%
2022 Q3	- KRW	0.0%
2022 Q2	- KRW	0.0%
2021 Q3	- KRW	-100.0%
2021 Q4	-10.00 KRW	0.0%
2021 Q1	- KRW	0.0%
2021 Q2	909.09 Million KRW	0.0%
2021 FY	909.09 Million KRW	0.0%
2020 Q4	- KRW	0.0%
2020 Q1	- KRW	0.0%
2020 Q2	- KRW	0.0%
2020 Q3	- KRW	0.0%
2020 FY	- KRW	0.0%
2019 Q1	- KRW	0.0%
2019 FY	- KRW	0.0%
2019 Q4	- KRW	0.0%
2019 Q3	- KRW	0.0%
2019 Q2	- KRW	0.0%
2018 Q2	- KRW	0.0%
2018 FY	- KRW	0.0%
2018 Q1	- KRW	0.0%
2018 Q4	- KRW	0.0%
2017 FY	- KRW	0.0%
2017 Q1	- KRW	0.0%
2017 Q4	- KRW	0.0%
2016 FY	- KRW	-100.0%
2015 FY	639.81 Million KRW	0.0%

Peer Revenue Comparison of Cellid, Co., Ltd.

Name	Revenue	Revenue Difference
Sam Chun Dang Pharm. Co., Ltd	192.66 Billion KRW	100.0%
Hyundai Bioscience Co., Ltd.	9.48 Billion KRW	100.0%
ST Pharm Co.,Ltd.	284.99 Billion KRW	100.0%
ABL Bio Inc.	65.54 Billion KRW	100.0%